For Healthcare Professionals

Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular Carcinoma

clipboard-pencil

About the study

An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

inclusion criteria:


  1. Locally advanced or metastatic hepatocellular carcinoma, confirmed by histology/cytology.
  2. Disease progression after surgery and / or local treatment.
  3. Previous standard systemic treatments for advanced hepatocellular carcinoma have failed or developed intolerable toxicity.

EXCLUSION CRITERIA

exclusion criteria:


  1. Histology contains fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma and other components.
  2. Have a history of hepatic encephalopathy, or have a history of liver transplantation.
  3. Diffuse liver cancer.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Advanced Hepatocellular Carcinoma

Age (in years)

18 - 75

Phase

Phase 1

Participants needed

97

Est. Completion Date

Apr 30, 2023

Treatment type

Interventional


Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

ClinicalTrials.gov identifier

NCT04401813

Study number

CIBI310C101

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.